长春瑞滨联合顺铂治疗蒽环类和紫杉类耐药晚期乳腺癌的临床研究  

Clinical study of vinorelbine plus cisplatin in treatment of advanced breast cancer with anthracyclines and taxanes resistance

作　　者：于晶琳[1] 赵玉亮[1] 方红[1] 林蓉燕[1] 孙明霞[1] 

机构地区：[1]北京大学第一医院肿瘤化疗科,北京100034

出　　处：《中国肿瘤临床与康复》2010年第1期24-26,共3页Chinese Journal of Clinical Oncology and Rehabilitation

摘　　要：目的评估长春瑞滨联合顺铂方案治疗蒽环类和紫杉类耐药晚期乳腺癌的近期疗效和安全性。方法对37例蒽环类和紫杉类耐药的晚期乳腺癌患者采用长春瑞滨25mg/m2,静脉滴注30min,第1、8天;顺铂40mg/m2,静脉滴注,第1、2天。3周为1个周期。每2～3个周期后进行一次客观疗效评价。所有患者随访均超过6个月。结果37例患者中完全缓解(CR)0例,部分缓解(PR)16例(43.2%),稳定(SD)14例(37.8%),进展(PD)7例(18.9%);总有效率(CR+PR)43.2%。中位疾病进展时间(TTP)5.5个月。本方案的主要毒副作用为Ⅱ/Ⅲ度中性粒细胞减少、胃肠道反应和静脉炎。结论长春瑞滨联合顺铂3周方案治疗蒽环类和紫杉类耐药的晚期乳腺癌患者具有良好的疗效和较低的毒副作用。Objective To evaluate the efficacy and safety of vinorelbine（NVB） plus cisplatin（DDP） in treatment of patients with advanced breast cancer after the failure of treatment with anthracyclines and taxanes.Methods Thirty-seven cases of advanced breast cancer with anthracyclines and taxanes resistance were treated with NVB（25mg/m^2,day 1,day 8） and DDP（40 mg/m^2,day 1,day 2）.Three weeks constituted one cycle.After 2 ～ 3 cycles of chemotherapy the response rate and side effects were evaluated.All cases were followed up for more than 6 months.Results All the 37 cases were evaluated for recent objective response.16 cases（43.2%） had partial response（PR）,while 14 cases（37.8%） had stable disease（SD） and 7 cases（18.9%） showed progressive disease（PD） ;the overall response rate was 43.2%.The median time to progression（TTP） was 5.5 months.Main side effects were grade 2 /3 neutropenia,gastrointestinal tract toxicity and phlebitis.Conclusions The combination of vinorelbine and cisplatin is effective and safe in the treatment of advanced breast cancer with anthracyclines and taxanes resistance.

关 键 词：乳腺肿瘤/化学疗法 长春瑞滨 顺铂 蒽环类 紫杉类 

分 类 号：R737.9[医药卫生—肿瘤] R730.53[医药卫生—临床医学]